Pharmacokinetics and Safety of Transdermal Megestrol Acetate

Withdrawn before enrolling · Phase 4

Conditions studied: Cachexia

In brief

Rationale: Megestrol acetate (Megace®) is a progestin analog that is FDA approved for the palliative treatment of breast and endometrial carcinoma. It is also commonly used as an appetite stimulant, particularly in HIV and cancer patients with poor appetite from their primary disease and/or their therapy. Megace is well absorbed orally, however, many patients, particularly younger ones have difficulty taking oral medications. Transdermal progestins are available and are FDA approved. For example, Ortho EvraTM is a transdermal contraceptive patch containing an estrogen (ethinyl estradiol) and a progestin (norelgestromin). Key Objectives: Compare the pharmacokinetics of orally administered vs. transdermal Megace and determine if there are any local side effects of the transdermal route.

Key facts

Study ID

NCT00163072

Run by

Milton S. Hershey Medical Center

People needed

0

Starts

2005-10-01

Expected to finish

2012-12-01

Last updated by the study team

2013-10-25

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients of any age who are already receiving oral Megace as an appetite stimulant.
• Patients must have an indwelling IV catheter in order to draw drug levels.

You may not qualify if…

• Known hypersensitivity to the transdermal vehicle.
• Taking any other medicine that would interfere with the Megace assay.
• Weight less than 10 kg.

Where it is running

• Hershey Medical Center — Hershey, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.